Edinburgh Research Explorer

Myelin regulatory factor drives remyelination in multiple sclerosis

Research output: Contribution to journalArticle

  • Greg J Duncan
  • Jason R Plemel
  • Peggy Assinck
  • Sohrab B Manesh
  • Fraser G W Muir
  • Ryan Hirata
  • Matan Berson
  • Jie Liu
  • Michael Wegner
  • Ben Emery
  • G R Wayne Moore
  • Wolfram Tetzlaff

Related Edinburgh Organisations

Open Access permissions

Open

Documents

  • Download as Adobe PDF

    Accepted author manuscript, 1.11 MB, PDF document

    Licence: Creative Commons: Attribution Non-Commercial (CC-BY-NC)

Original languageEnglish
Pages (from-to)403-422
Number of pages20
JournalActa Neuropathologica
Volume134
Issue number3
Early online date19 Jun 2017
DOIs
Publication statusPublished - Sep 2017

Abstract

Remyelination is limited in the majority of multiple sclerosis (MS) lesions despite the presence of oligodendrocyte precursor cells (OPCs) in most lesions. This observation has led to the view that a failure of OPCs to fully differentiate underlies remyelination failure. OPC differentiation requires intricate transcriptional regulation, which may be disrupted in chronic MS lesions. The expression of few transcription factors has been differentially compared between remyelinating lesions and lesions refractory to remyelination. In particular, the oligodendrocyte transcription factor myelin regulatory factor (MYRF) is essential for myelination during development, but its role during remyelination and expression in MS lesions is unknown. To understand the role of MYRF during remyelination, we genetically fate mapped OPCs following lysolecithin-induced demyelination of the corpus callosum in mice and determined that MYRF is expressed in new oligodendrocytes. OPC-specific Myrf deletion did not alter recruitment or proliferation of these cells after demyelination, but decreased the density of new glutathione S-transferase π positive oligodendrocytes. Subsequent remyelination in both the spinal cord and corpus callosum is highly impaired following Myrf deletion from OPCs. Individual OPC-derived oligodendrocytes, produced in response to demyelination, showed little capacity to express myelin proteins following Myrf deletion. Collectively, these data demonstrate a crucial role of MYRF in the transition of oligodendrocytes from a premyelinating to a myelinating phenotype during remyelination. In the human brain, we find that MYRF is expressed in NogoA and CNP-positive oligodendrocytes. In MS, there was both a lower density and proportion of oligodendrocyte lineage cells and NogoA+ oligodendrocytes expressing MYRF in chronically demyelinated lesions compared to remyelinated shadow plaques. The relative scarcity of oligodendrocyte lineage cells expressing MYRF in demyelinated MS lesions demonstrates, for the first time, that chronic lesions lack oligodendrocytes that express this necessary transcription factor for remyelination and supports the notion that a failure to fully differentiate underlies remyelination failure.

    Research areas

  • 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase/metabolism, Animals, Corpus Callosum/metabolism, Humans, Mice, Mice, Knockout, Multiple Sclerosis/metabolism, Nogo Proteins/metabolism, Oligodendroglia/metabolism, Remyelination/physiology, Spinal Cord/metabolism, Transcription Factors/genetics

Download statistics

No data available

ID: 133870196